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 Toll-like receptors (TLRs), members of the innate immune system, recognize 
distinctive components of pathogens to initiate cellular signaling pathways.  These 
pathways lead to the production of inflammatory proteins such as tumor necrosis factor 
alpha (TNFα), a cytokine that activates immune cells to fight the infection.  When 
infections disseminate into the bloodstream, TLR-signaling is activated systemically and 
the excessive release of cytokines, chemokines, and other inflammatory mediators 
produces a life-threatening condition known as septic shock.  The majority of drugs 
recently developed to treat septic shock were beneficial in animal and in vitro models, but 
were ineffective in human clinical trials.  One possible solution to resolve this disparity is 
to use the new animal model Danio rerio (zebrafish) whose unique characteristics allow 
for high-throughput, large-scale screening of chemicals and for exclusive study of the 
innate immune system.  
 We undertook three different approaches to establish a functioning transgenic 
zebrafish model that facilitates visualization of TNFα expression as an indicator of TLR 
signaling and pathologic immune response.  The first expression clone contains the 
human TNFα (hTNFα) enhancer and the enhanced green fluorescent (EGFP) reporter 
gene under control of the basal carp β-actin promoter.  The second expression clone 
contains all elements of the first clone with the addition of a red fluorescent reporter 





promoter (Cry), to facilitate preselection of putative transgenic founders.  The third 
expression clone is a modified BAC clone containing the red fluorescent reporter gene 
tandem-dimer Tomato (tdTomato) fused to the zebrafish TNFα (zTNFα) gene in its 
genomic context. 
 We successfully introduced the modified BAC clone into the germline of two 
male zebrafish.  To date, one female offspring from an F0 founder has been identified as 
carrying the BAC transgene.  In the future, the F2 embryos from this F1 female will be 
analyzed for expression of the fluorescent fusion protein under conditions which induce 
TNFα production.  Additionally, future establishment of a homozygous transgenic 
generation will allow functional studies of TLR signaling during infections and 
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1.1 Sepsis and Septic Shock 
 
 Sepsis is a serious medical condition arising from a localized tissue infection that 
cannot be contained and then disseminates into the bloodstream.  Despite modern 
advances in medicine, sepsis has continued to be a lethal problem that is increasing in 
frequency (LEE and SLUTSKY 2010).  “Shock due to sepsis is the most common cause of 
mortality in patients in non-coronary intensive care units” (LOLIS and BUCALA 2003).  
Sepsis is ranked as the 10th leading cause of death overall in the United States, and kills 
20-50% of severely affected patients (WHEELER and BERNARD 1999; MARTIN et al. 2003; 
XU 2010).  The resulting sequelae of sepsis are caused by excessive release of cytokines, 
chemokines, and other inflammatory mediators into the circulation.  The repercussion of 
this “cytokine storm” is the development of systemic inflammatory response syndrome 
(SIRS).  SIRS, in the presence of confirmed or suspected infection, is defined as sepsis.  
Clinically, systemic inflammatory response syndrome (SIRS) manifests as fever or 
hypothermia (>38°C or <36°C), tachycardia (>90 beats per minute), tachypnea (>20 
breaths per minute), and leukocytosis or leucopenia (<4000 white blood cell per μL or 
>12,000 white blood cells per μL, or presence of >10 percent immature granulocytes) 
(JAESCHKE et al. 2008).  Sustained neutrophil activation and adherence to vascular 
endothelial cells causes endothelial dysfunction and damage.  The permeability of the 





reduced, and blood flow to vital organs is decreased (DE GAUDIO et al. 2009).  Severe 
sepsis develops when organ dysfunction, hypoperfusion (decreased blood flow through 
an organ), and hypotension (low blood pressure: systolic blood pressure less than 90 
millimeters of mercury [mm Hg] or diastolic less than 60 mm Hg) are present.  If fluid 
resuscitation fails to correct the hypotension, the body goes into septic shock.  All of the 
tissues and organs now lack sufficient blood flow.  Septic shock ultimately leads to 
multiple organ dysfunction syndrome (MODS) that almost invariably results in death 
(JAESCHKE et al. 2008; DE GAUDIO et al. 2009).  
 
1.2 Therapy and Animal Models of Sepsis 
 Few new therapies have been identified for treating sepsis.  The majority of drugs 
that proved successful in animal and in vitro models demonstrated ineffective results in 
human clinical trials (LEE and SLUTSKY 2010).  Lipopolysaccharide (LPS), also referred 
to as endotoxin, is a cell-wall component of Gram-negative bacteria.  Approximately half 
the cases of sepsis are due to Gram-negative bacterial infections (LOLIS and BUCALA 
2003; MARTIN et al. 2003).  Clinical trials for treating sepsis with a novel human 
monoclonal antibody against endotoxin, HA-1A, resulted in no decrease of mortality 
(LUCE 1993).  A separate clinical trial for severe sepsis treatment used a chimeric 
antibody against the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα).  The 
antibody did not alter the pattern of cytokine activation or reduce systemic inflammatory 
symptoms (CLARK et al. 1998).  Similar results were observed in a different trial using 
monoclonal anti-TNFα antibodies (ABRAHAM 1999).  Unexpectedly, the anti-TNFα 
therapies demonstrated beneficial and effective treatment for the chronic inflammatory 
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diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis 
(CHEN et al. 2006; NERI et al. 2010).   
 The lack of benefits demonstrated from the anti-endotoxin and anti-TNFα human 
clinical trials is troubling.  Mouse, rat, rabbit, dog, pig, sheep, and nonhuman primate 
animal models were used in the preclinical experiments of anti-endotoxin and anti-TNFα 
(POLI-DE-FIGUEIREDO et al. 2008; DYSON and SINGER 2009).  The disparity between 
preclinical and clinical data has been observed with other modern drugs; for example, 
drugs used in chemotherapy of cancer.  Starting in 1955, the formal screening of 
thousands of drugs have shown benefit in either cell or animal models;  however, there 
are only 39 drugs that have gained approval from the U.S. Food and Drug Administration 
for use as a chemotherapy agent (GURA 1997).  Hence, animal models that are not good 
predictors of human disease and drug responsiveness are not unique to anti-endotoxin and 
anti-TNFα therapy.  One possible solution would be trying a novel animal model with 
advantageous characteristics that provide different perspectives of the immune system 
and is amendable to large-scale compound screens.  Although animal models will never 
be optimal for reproducing human disease, the zebrafish, Danio rerio, is a promising 
animal model for drug discovery.  While evolutionarily and physiologically more distant 
to humans than other animal models, the unique features of zebrafish allow for high-







1.3 Advantages of the Zebrafish Animal Model 
1.3.1 Inherent Characteristics and Developed Techniques 
Several inherent characteristics and developed techniques make zebrafish a 
promising experimental model for Toll-like receptor (TLR) signaling.  A mating pair can 
produce 200-300 new progeny each week (MEEKER and TREDE 2008).  Ova fertilization 
and embryo development occurs ex vivo.  Embryos are translucent for several days, 
allowing for visualization of development, immune cell movement, fluorescent protein 
reporters such as GFP (green fluorescent protein), and fluorescently-labeled bacteria or 
viruses (MEEKER and TREDE 2008; ALLEN and NEELY 2010).  Fluorescent reporters can 
be placed under the control of tissue-specific promoters or enhancer elements, allowing 
specific cell types such as neutrophils to be visualized or tracked in vivo using fluorescent 
microscopy (ALLEN and NEELY 2010; LOYNES et al. 2010).  Green fluorescent protein 
(GFP) was originally identified in the Aequorea victoria jellyfish (SHIMOMURA et al. 
1962).  Several properties of GFP have been modified for its use in research.  Enhanced 
GFP (EGFP) contains a single-point mutation (S65T) in comparison to wild-type GFP 
that eliminates one of the bimodal excitation peaks seen in wild-type GFP.  EGFP is 
highly photostable and can be imaged using fluorescein isothiocyanate (FITC) filter sets.  
DsRed, a red fluorescent protein, was isolated and cloned from a coral belonging to the 
Discosoma genus.  Tandem-dimer tomato (tdTomato) fluorescent protein is a derivative 
of DsRed (SHANER et al. 2004; SHANER et al. 2007; RIZZO et al. 2009). 
 Other advantages are that in young zebrafish, it is possible to study innate 
immunity exclusively.  A fully functional adaptive immune system does not develop for 
four-six weeks (SULLIVAN and KIM 2008).  Important constituents of the innate immune 
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system, specifically monocytes, granulocytes, and tissue macrophages, are present in 
bony fish.  Embryos at 23-26 hours postfertilization (hpf) have early macrophages 
capable of phagocytosis.  These early macrophages differentiate in the free space 
between the yolk cell and epidermis.  This locale is easily visible with video-enhanced 
differential interference contrast (DIC) microscopy allowing cells to be imaged and 
tracked in vivo at high magnification (TRAVER et al. 2003).  Furthermore, macrophage 
interaction with other blood cells or with intravenously injected microbes can be imaged 
in this free space.  These interactions are feasible because venous blood flows freely over 
the surface of the yolk cell without being confined to a blood vessel at the start of 
circulation and is then collected in the heart (TRAVER et al. 2003; LEVRAUD et al. 2008).  
 The entire zebrafish genome has been sequenced multiple times and is 
continuously being assembled and reassembled (http://uswest.ensembl.org/Danio_rerio/ 
Location/genome).  The genetic map of zebrafish reveals highly conserved synteny with 
the human genome (TRAVER et al. 2003; JAULT et al. 2004; MEIJER et al. 2004).  Teleosts 
or bony fish have a highly developed complement system.  Major inflammatory proteins 
are present in fish, namely, TNFα; nuclear factor-kappaB (NF-кB); cyclooxygenase 2 
(COX-2); interleukin 1 (IL-1); IL-8; and other CC and CXC chemokines (TRAVER et al. 
2003).  Homologs of the human IL-1 and IL-18 receptors have been identified in the 
zebrafish genome.   
Techniques for chemical screens in zebrafish have been established.  Embryos are 
small enough to be arrayed in 96-well plates facilitating large-scale in vivo chemical 
screens.  Chemical compounds can simply be added to the water, and, using high-
throughput in situ hybridization or transgenic reporter lines of zebrafish, the read-out of 
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their functional consequences is straight-forward (TREDE et al. 2004).  In addition to 
systemic drug administration, tissue-specific drug delivery can be achieved by 
electroporation (THUMMEL et al. 2006; HENDRICKS and JESUTHASAN 2007).  Chemical 
screens in live zebrafish are unbiased; the molecular target does not have to be pre-
determined.  Chemicals that restore gene function can be identified.  Small molecule 
screens in zebrafish have already shown potential to translate into clinical benefits.  The 
first human trial of a drug to maximize bone marrow transplants was precipitated by 
experiments performed in zebrafish that identified prostaglandin E2 (PGE2) as an inducer 
of stem cell expansion (DURAND and ZON 2010).   
  Efficient forward and reverse genetic screening techniques have been developed 
for the zebrafish model including targeting induced local lesions in genome (TILLING), 
gene knockdown using morpholino oligonucleotides, and transgenesis using the natural 
fish Tol2 transposase (TREDE et al. 2004; MEEKER and TREDE 2008).  The Tol2 
transposition system has been successfully utilized for transgenesis in zebrafish with high 
efficiency.   On average, 50-70% of zebrafish embryos injected with vectors containing 
the Tol2 sites produce transgenic F1 offspring (KAWAKAMI et al. 2004b; URASAKI et al. 
2006).   Transgenic fish created with the Tol2 system have been shown to express GFP 
beyond the F5 generation (KAWAKAMI 2005).  Tol2 has also been shown to transpose in 
frogs, Xenopus laevis and Xenopus tropicalis, chicken embryos, and mouse embryonic 
stem cells (KAWAKAMI et al. 2004a; KAWAKAMI and NODA 2004; HAMLET et al. 2006; 
KAWAKAMI 2007; SATO et al. 2007).  Tol2 can transpose into somatic or germ line cells 
and can transpose over a range of temperatures, 25°-26°C in zebrafish, and 37°-38°C in 
chicken embryos.  The Tol2 transposition does not cause gross rearrangements of 
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surrounding genomic DNA and has no required genome target specificities (KAWAKAMI 
2007).  A Tol2 vector can facilitate up to 11 kilobases (kb) of DNA insert without 
reducing the transpositional activity (URASAKI et al. 2006).  In addition, the Tol2 
transposon system has been developed for gene trapping and enhancer trapping methods 
in zebrafish. 
A high-throughput automated cell-injection system has been created for 
introducing materials into zebrafish embryos.   The automated system is capable of 
depositing a precise volume of liquid material into an embryo.  Several destinations 
within the embryo can be chosen for the targeted material. The automated system is 
capable of injecting 15 embryos per minute with a 99% success rate.  Survival rate of the 
injected embryos is 98% (WANG et al. 2007).   
 
1.3.2 Zebrafish as a Tool for Mammalian Infection 
 Successful infections in zebrafish with both Gram-positive and Gram-negative 
bacteria have been demonstrated.  Infections have been achieved with both natural fish 
pathogens and genuine human pathogens (O'CALLAGHAN and VERGUNST 2010; 
VERGUNST et al. 2010).   For example, extraintestinal pathogenic Escherichia coli, 
Edwardsiella tarda, Burkholderia cenocepacia, Aeromonas salmonicida, Pseudomonas 
aeruginosa, Staphylococcus aureus, Aeromonas hydrophila, Streptococcus iniae, 
Streptococcos pyogenes, Mycobacterium marinum, Salmonella typhimurium, Listeria 
species, and Flavobacterium columnare have all been shown to infect zebrafish 
(PRESSLEY et al. 2005; LIN et al. 2007; RODRIGUEZ et al. 2008; SULLIVAN and KIM 2008; 
BRANNON et al. 2009; WILES et al. 2009; ORDAS et al. 2010; VERGUNST et al. 2010).  
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Bacterial infection can be achieved by injection into adults and embryos, or by immersion 
following dermal abrasion of adults or removal of the chorion from embryos.  The 
ensuing inflammatory reactions can be measured by various methods such as real-time 
quantitative polymerase chain reaction (PCR).   For instance, infection with Edwardsiella 
tarda showed significantly increased levels of TNFα and IL-1β (PRESSLEY et al. 2005), 
while infection with Aeromonas hydrophila demonstrated an increase in TNFα, IL-1β, 
and IFNγ levels as measured by quantitative PCR (RODRIGUEZ et al. 2008).  Artificial 
LPS has also been shown to induce inflammatory reactions in zebrafish (WATZKE et al. 
2007).   
 In addition to the many similarities, there are also differences between the 
zebrafish and human response to infection.  In humans, it is Toll-like receptor 4 (hTLR4) 
that recognizes endotoxin, the lipopolysaccharides (LPS) of Gram-negative bacteria, and 
initiates an immune response.  In zebrafish, two TLRs have been identified that resemble 
human TLR4, referred to as zTLR4a and zTLR4b [Table 1].  However, functional studies 
in zebrafish have demonstrated that zTLR4a and zTLR4b do not respond to LPS because 
of the structural difference in their extracellular domains.   Therefore, zTLR4a and 
zTLR4b are paralogs to hTLR4, not homologs.  Other differences exist between zebrafish 
and mammalian immunology.  For example, in adult zebrafish, hematopoiesis occurs in 
the head kidney, as opposed to the bone marrow in mammals. Teleosts do not have 
lymph nodes; in comparison, the spleen is the site of antigen presentation and T cell-B 
cell interactions.  Lymphoid aggregates are present in the lamina propria of the gut in 
teleosts, but the aggregates are not histologically distinguishable as Peyer’s patches.   
Only two immunoglobulin (Ig) heavy chain isotypes are present in teleosts, IgM and IgD 
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(TRAVER et al. 2003).  However, despite the differences, the many advantages of 
zebrafish and the similarities to human infection response make zebrafish an attractive 
model to study antimicrobial immune responses and to screen for novel compounds that 
may be used clinically.  
 
1.4 Toll-like Receptor Signaling 
 Toll-like receptors (TLRs) are an important class of pathogen recognition 
receptors (PRRs) that are involved in the innate immune response to bacterial infection.  
Toll-like receptors are expressed by various immune and nonimmune cells such as 
epithelial cells (AKIRA et al. 2006).  TLRs recognize biochemical components, referred to 
as pathogen-associated molecular patterns (PAMPs), that distinguish bacteria, fungi, 
parasites, and viruses from multicellular animals (CINEL and OPAL 2009).  TLRs also 
recognize endogenous damage/danger-associated molecular patterns (DAMPs), such as 
heat-shock proteins, neutrophil elastase, or fibrinogen (TSUJIMOTO et al. 2008).  TLRs 
recognize their ligands at the plasma membrane and within endosomes, lysosomes, and 
endolysosomes (KAWAI and AKIRA 2010).   
 Ten functional Toll-like receptors (TLRs) have been identified in humans, 
designated TLR1-10 [Appendix A and Appendix B].  Fifteen putative variants of Toll-
like receptors have been identified in the zebrafish genome, including 10 homologs to 
mammalian TLR genes and a fish-specific group of TLRs [Table 1] (JAULT et al. 2004; 
MEIJER et al. 2004; SULLIVAN and KIM 2008).  At least 15 zebrafish TLR genes, 
abbreviated zTLR, are expressed at one day postfertilization (dpf) when the first 
macrophages and neutrophils enter the blood circulation (JAULT et al. 2004; MEIJER et al. 
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2004; VAN DER SAR et al. 2006).  Sequencing of cloned zTLR2, zTLR4b, and zMyD88 
genes identified the same intron-exon organization present in human TLR2, TLR4, and 
MyD88 genes (JAULT et al. 2004; MEIJER et al. 2004; VAN DER SAR et al. 2006).     
 Toll-like receptors (TLRs) are named for their homology to the Drosophila Toll 
receptor.  The Toll protein is crucial to dorsal-ventral polarity in Drosophila embryos.  In 
the adult Drosophila, the Toll protein is essential to the innate immune response against 
fungal infection (MEDZHITOV et al. 1997; AKIRA and TAKEDA 2004).  The extracellular 
domain of Toll-like receptors contains 19-25 tandem copies of leucine-rich repeat (LRR) 
motifs.  The LRR domains form a concave or indented surface important to microbial 
recognition (JIN and LEE 2008).  The cytoplasmic portion of Toll-like receptors have a 
conserved region of approximately 200 amino acids, termed Toll/interleukin-1 receptor 
(TIR) domain for its parallel properties to interleukin-1 receptor.  The TIR domain has 
three conserved regions theorized to be important for protein binding and receptor 
localization (BELVIN and ANDERSON 1996; IMLER and HOFFMANN 2001; WEBER et al. 
2003; AKIRA and TAKEDA 2004; RALLABHANDI et al. 2006; KAWAI and AKIRA 2010).  
  Subsequent to ligand binding, Toll-like receptors dimerize, either as homodimers 
or heterodimers, and the TIR domain undergoes conformational changes that recruit a 
specified adaptor protein to elicit a specific immune response.  There are four adaptor 
proteins: myeloid differentiation primary-response protein 88 (MyD88), TIR-associated 
protein or MyD88-adaptor-like (TIRAP/MAL), TIR-domain-containing adaptor protein-
inducing IFN-β or Toll-IL-1 receptor-containing adaptor molecule 1(TRIF/TICAM-1), 
and TRIF-related adaptor molecule (TRAM).  Zebrafish homologs of the human adaptor 
proteins and a negative regulator of TRIF-dependent TLR signaling (SARM) have been 
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identified, suggesting conservation of TLR signaling pathways from teleosts to mammals 
[Table 2].  In mammals, MyD88 can be recruited by all TLRs except TLR3.  The TRIF 
adaptor is recruited by TLR3 and TLR4 to elicit a type I interferon response to viruses.  
All of the adaptor proteins have a carboxy-terminal (C-terminal) TIR domain, enabling 
complementary association with the TLR dimers, and an amino-terminal (N-terminal) 
death domain (DD) for subsequent recruitment of kinases (IMLER and HOFFMANN 2001; 
AKIRA and TAKEDA 2004; AKIRA et al. 2006; KAWAI and AKIRA 2010).     
 TLR signaling pathways are categorized as MyD88-dependent or TRIF-
dependent.  Association of MyD88 with TLRs results in the recruitment of IL-1 receptor-
associated kinases, IRAK1 and IRAK4, to MyD88 through complementary death 
domains.  IRAK4 becomes activated and phosphorylates IRAK1.  Phosphorylated 
IRAK1 then associates with TRAF6, tumor-necrosis-factor-associated factor 6, thereby 
activating the ubiquitin E3-ligase function of TRAF6.  In partnership with an ubiquitin 
E2 complex, TRAF6 catalyzes the synthesis of polyubiquitin chains that provide a 
temporary structure for recruiting both the TAK1 (transforming-growth-factor-β-
activated kinase) and the IкB kinase (IKK) complexes.  The large IкB kinase (IKK) 
complex consists of three subunits, IKK-α, IKK-β, and IKK-γ or NEMO (nuclear factor-
кB essential modulator), and is a convergence point for many signaling pathways that 
lead to activation of the transcription factor nuclear factor-kappaB (NF-кB).  It is the 
IKK-β subunit that subsequently phosphorylates the inhibitor of NF-кB, IкB, marking the 
IкB protein for rapid degradation.  As a result, NF-кB is released from the inhibitor, 
exposing its nuclear localization signal, allowing translocation of the transcription factor   
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Table 1:  Identified TLR Genes in Zebrafish.  Data summarized from (JAULT et al. 2004; 




Table 2:  Identified TLR-signaling Genes and IL-Receptor Genes in Zebrafish.  Data 
summarized from (JAULT et al. 2004; MEIJER et al. 2004; PHELAN et al. 2005; SULLIVAN 
et al. 2007; SULLIVAN et al. 2009; LIU et al. 2010).  
 
Zebrafish (z) Gene Homolog 
zMyD88 
Human MyD88 (hMyD88); 
Fugu rubripes MyD88 (fMyD88); 
Drosophila MyD88 (dMyD88) 
zTIRAP hTIRAP; fTIRAP 
zTRIF hTRIF; fTRIF 
zSARM hSARM; fSARM 
zIL-1R hIL-1R 




Zebrafish (z) TLR 
Gene per Jault et al. 
Zebrafish (z) TLR Gene 
per Meijer et al. Homolog 
zTLR 1.1 zTLR 1 
Human TLR 1 (hTLR1); 
Fugu rubripes TLR 1 (fTLR 1) 
zTLR 1.2  hTLR 2 
zTLR 2 zTLR 2 hTLR 2; fTLR 2 
zTLR 3 zTLR 3 hTLR 3; fTLR 3 
zTLR 4.1a, 4.1b zTLR 4a, 4b hTLR 4 
zTLR 5 zTLR 5a, 5b hTLR 5; fTLR 5 
zTLR 7a, 7b zTLR7 hTLR 7; fTLR 7 
zTLR 8.1 zTLR 8a, 8b hTLR 8; fTLR 8 
zTLR 8.2  hTLR 8 
zTLR 9 zTLR 9 hTLR 9; fTLR 9 
 zTLR 18 fTLR 18 
 zTLR 19  
 zTLR 20a, 20b  
zTLR 21.1 zTLR 21 fTLR 21 
zTLR 21.2  fTLR 21 
zTLR 21.3  fTLR 21 
zTLR 21.4a, 21.4b  fTLR 21 
zTLR 21.5  fTLR 21 
 zTLR 22 fTLR 22a, 22b 
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across the nuclear membrane.  DNA binding of NF-кB recruits RNA polymerase to 
initiate transcription of several genes including pro-inflammatory cytokines and 
chemokines, such as tumor necrosis factor alpha (TNFα), interleukin-1 (IL-1), IL-6, IL-
12, type I interferons (IFNs), IL-8, and macrophage inflammatory protein-1 alpha (MIP-
1α), depending on cell type and ligand (BEUTLER and RIETSCHEL 2003; AKIRA and 
TAKEDA 2004; JIMI and GHOSH 2005; LIU and MALIK 2006; VERSTREPEN et al. 2008).   
 In Gram-negative sepsis, it is Toll-like receptor 4 (TLR4) that recognizes 
endotoxin or lipopolysaccharide (LPS) and initiates cellular signaling [Table 1].  
Monocytes from septic patients were found to have considerable increase in TLR2 and 
TLR4 expression compared to healthy individuals (TSUJIMOTO et al. 2008).  Prior to 
TLR4 recognition, LPS is bound by LPS-binding protein (LBP) and by soluble cluster-
of-differentiation-14 (sCD14) protein present in plasma.  LBP and sCD14 catalytically 
transfer LPS to the membrane-bound CD14 (mCD14), a receptor anchored to the surface 
of macrophages by glycosylphosphatidylinositol (GPI).  However, mCD14 does not have 
an intracellular signaling domain and it must deliver LPS to a TLR4/MD-2 receptor 
complex.  Myeloid differentiation protein-2 (MD-2) is a secreted protein required for 
optimal TLR4-mediated signaling.  MD-2 binds the extracellular domain of TLR4 
forming a TLR4/MD-2 receptor complex.  (SCHUMANN et al. 1990; SCHLETTER et al. 
1995; YANG et al. 1996; AKASHI et al. 2000; MIYAKE et al. 2000; BEUTLER and 
RIETSCHEL 2003; RALLABHANDI et al. 2006).  TLR4/MD-2 dimerization at the plasma 
membrane preferentially initiates MyD88-dependent signaling via the co-adaptor TIRAP 
to activate NF-кB.  Interestingly, the dimerized TLR4/MD-2 receptor complex is 
subsequently endocytosed, releasing the TIRAP/MyD88 complex.  This allows the co-
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adaptor TRAM and the adaptor TRIF to interact with TLR4 and induce intracellular, 
TRIF-dependent signaling.  This signaling pathway specifically leads to IFN-β 
production (KAGAN et al. 2008).  Although the zebrafish TLR4 paralogs do not respond 
to LPS, exposure to the Gram-negative Edwardsiella tarda bacteria resulted in increased 
expression of the homologous signaling proteins zTLR3, zIRAK-4, and zTRAF6.  In 
mammals, TRAF6 is a central intracellular, pro-inflammatory signaling protein used by 
all known mammalian TLRs, and is involved in antiviral and antibacterial responses 
(PHELAN et al. 2005).   
 The importance of the MyD88-dependent signaling pathway can be demonstrated 
by animal models and human patients deficient in key signaling proteins.  MyD88-
deficient mice infected with a virulent strain of Mycobacterium avium or with 
Staphylococcus aureus showed a considerably decreased immune response to both 
pathogens in comparison to wild-type mice (TAKEUCHI et al. 2000; FENG et al. 2003).  
Morpholino knockdowns of MyD88 in zebrafish embryos revealed impaired clearance of 
Salmonela enteric serovar Typhimurium Ra bacteria (VAN DER SAR et al. 2006).  
C3H/HeJ mice with mutated TLR4 were shown to be highly susceptible to infection by 
Salmonella typhimurium or Neisseria meningitis (AKIRA et al. 2006).  In humans, a point 
mutation within the TLR4 gene causes an amino acid change in the extracellular domain 
of the receptor and is associated with increased risk of Gram-negative bacterial infection 
and an increased incidence of systemic inflammatory response syndrome (COOK et al. 
2004; SCHWARTZ and COOK 2005; RALLABHANDI et al. 2006).  Experiments using 
monocytes from humans with inherited IRAK4 deficiency demonstrated an absence of 
NF-кB activation.  The IRAK4-deficient patients were susceptible to Gram-positive 
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Streptococcus pneumoniae and Staphylococcus aureus infections (PICARD et al. 2003).  
Mice lacking p50, a subunit of NF-кB, were unable to sufficiently eliminate infection 
with Listeria monocytogenes and were more susceptible to Streptococcus pneumonia 
infection (SHA et al. 1995).  Interestingly, newborn mice lacking IкBα were  severely 
runted, had skin defects, and increased granulopoiesis.  The levels of nuclear NF-кB in 
thymocytes and splenocytes from these IкBα deficient mice were extremely elevated.  At 
seven days, the IкBα deficient mice died, suggesting continuously increasing NF-кB 
activity can be lethal (BEG et al. 1995).  Indeed, studies demonstrate correlation between 
NF-кB activity levels and disease severity in septic patients, where significantly higher 
levels are exhibited in nonsurviving patients compared to patients who survived 
(ARNALICH et al. 2000; LIU and MALIK 2006).   
 
1.5 Tumor Necrosis Factor Alpha 
Tumor necrosis factor alpha1
                                                 
1 The naming of tumor necrosis factor as TNF-alpha (α) is historical because TNF-beta (β) was 
subsequently designated as lymphotoxin.  TNF, TNFα, and the former term cachectin refer to the same 
protein. 
 (TNFα) is one of several pro-inflammatory 
cytokines activated by NF-кB.   TNFα activates and regulates inflammatory reactions and 
cells of the immune system.  TNFα is a major participant in LPS-mediated toxicity during 
sepsis (VOGL et al. 2007; DE GAUDIO et al. 2009).  Experiments have demonstrated the 
significant involvement of TNFα in sepsis and septic shock.  For example, when BALB/c 
mice were passively immunized against murine TNF, they were protected against the 
lethal effects of LPS (BEUTLER et al. 1985).  TNF by itself is capable of inducing the 
same pathophysiologic effects provoked by LPS.  This has been demonstrated in human 
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subjects, rats, goats, and dogs who received intravenous infusions of recombinant TNF 
(TRACEY et al. 1986; TRACEY et al. 1987; MICHIE et al. 1988).  In addition to septic 
shock, dysregulated TNF levels are associated with numerous diseases ranging from 
chronic inflammatory disorders to cardiovascular diseases to several forms of cancer 
(AGGARWAL et al. 2006; FALVO et al. 2010). 
The TNFα gene is an immediate early gene; it is transcribed rapidly in response to 
pathogens, stress, and other inflammatory proteins (FALVO et al. 2010).  The TNFα gene 
is located on chromosome six between class I human leukocyte antigen (HLA)-B and 
class II HLA-DR loci in a region of the human genome that is highly polymorphic, the 
major histocompatibility complex (MHC) (FALVO et al. 2010).  Regulation of TNFα gene 
expression has been shown to be cell type- and stimulus type-specific (FALVO et al. 2000; 
TSYTSYKOVA et al. 2007; FALVO et al. 2010).  Mononuclear phagocytes, such as 
macrophages, are the main producers of TNFα.  T cells, B cells, NK cells, mast cells, 
dendritic cells, and nonimmune fibroblasts also produce TNFα (FALVO et al. 2010).  
Receptors for TNFα, TNF-Receptor I and TNF-Receptor II, are present on almost all cell 
types (VAN DER POLL and LOWRY 1995).  These receptors, as well as pattern recognition 
receptors (PRRs), initiate cellular signaling pathways that lead to TNFα expression. 
Regulation of TNFα gene expression is achieved by various mechanisms; for example, 
chromatin remodeling and enhanceosome formation.  Repositioning of the nucleosomes 
proximal to the TNFα promoter regulates the accessibility of the promoter to 
transcription factors (EL GAZZAR et al. 2010).  Expression of TNFα can be rapidly 
upregulated by enhanceosome complexes.  These nucleoprotein complexes are composed 
of transcription factors and coactivators that bind to enhancer and promoter sequences.  
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This binding manipulates the DNA to form a higher-order structure that helps to increase 
the rate of transcription (FALVO et al. 2010).   
In summary, the majority of novel drugs developed in animal and in vitro models 
for the treatment of sepsis proved to be ineffective in human clinical trials, namely anti-
endotoxin and anti-TNFα.  Although animal models are not optimal for replicating 
human disease, the zebrafish, Danio rerio, has tremendous potential as an animal model 
for drug discovery.  The unique features of zebrafish, such as amendibility to high-
throughput, large-scale screening of chemicals, the ability to study the innate immune 
system exclusively in young zebrafish, and the identification of Toll-like receptor 
homologs, make zebrafish a promising model for studying signaling events involved in 









 The aim of this project is to establish a transgenic zebrafish model of signaling 
events following Toll-like receptor engagement.  This transgenic model will provide an 
unbiased, universal means for studying the functionality of zebrafish TLRs using 
morpholino knock-down experiments and testing of ligands, and for determining 
compounds and genes that affect TNFα production through large-scale chemical and 
genetic screening.  These studies could aid in the characterization and understanding of 
pathways that lead to sepsis and septic shock.  Additionally, this transgenic zebrafish 
model will serve as a versatile research tool for the scientific community to study 







3.1 Zebrafish Care and Experimental Techniques 
3.1.1 Maintenance and Handling 
 Zebrafish were handled and cared for according to the Institutional Animal Care 
and Use Committee (IACUC) guidelines.  See http://www.iacuc.org/, http://zfin.org, and 
http://www.nal.usda.gov/awic/pubs/noawicpubs/educ.htm for detailed information.  
 
3.1.2 Strain 
  *AB, pronounced star-AB, wild-type line was microinjected with the different 
expression clones.  Refer to http://zfin.org/action/genotype/detail?genotype.zdbID=ZDB-
GENO-960809-7 for further information. 
 
3.1.3 Sperm Squeezing, Breeding, and Tail Fin Clipping 
 Sexually-mature male zebrafish, at least 10-12 weeks old, were anesthetized with 
tricaine (3-aminobenzoic acid ethyl ester methanesulfonate) and placed belly-side up 
inside a slit of a dampened sponge.  Anal fins were placed to the sides of the fish, and the 
anal area was dabbed with a Kimwipe to remove excess water that can activate sperm.  
Sperm were collected into 1.5 μL glass capillary tubes by gently squeezing underneath 
and somewhat posterior to the anus with forceps.  The male fish were then isolated in 





consciousness, and the fish remained in isolation until their sperm was screened by PCR.  
Males that were positive by PCR were placed back on the water system and separated to 
maintain identification. 
 On the evening before spawning, male and female zebrafish were placed in a 
small breeding tank and separated by a divider.  Spawning and subsequent embryo 
formation occurred the following morning after removal of the divider.  Embryos were 
incubated at 28.5°C in E3 water supplemented with methylene blue, an antifungal and 
antibacterial compound.  Maintenance of the embryos included daily water changes and 
removal of dead embryos.  Hatched larvae were added to the nursery section of the 
recirculating water system where larvae received specialized feeding.  After 28 days, 
juvenile zebrafish were moved to an adult section within the recirculating system 
(LEVRAUD et al. 2008). 
 Prior to clipping the tail fin, zebrafish were anesthetized with tricaine.  
Anesthetized fish were then placed on plastic lid and a small section of the top of the tail 
fin was removed with a razor blade.  The fish were then isolated in separate smaller tanks 
with appropriate water lacking tricaine to ensure restoration of consciousness, and the 
fish remained in isolation until their tail fin DNA was screened by PCR.  Zebrafish that 
were positive by PCR were placed back on the water system and separated to maintain 
identification. 
  
3.1.4 DNA Extractions and PCR Screening of Zebrafish 
 DNA from sperm, embryos, and tail fin clippings was extracted using a modified  
HotSHOT (hot sodium hydroxide and Tris) Protocol (MEEKER et al. 2007).  Tissues were 
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placed into a microcentrifuge tube containing 50 mM NaOH: 50 μL for sperm, 75-100 μL 
per 20-30 embryos, and 100 μL for clipped tails.  Specimens in NaOH were vortexed, 
microcentrifuged, and then heated to 98°C for 10-20 minutes using a thermocycler.  After 
cooling, one-tenth the volume of 1M Tris-HCl at pH of 8.0 was added to each specimen 
for a final dilution of 1:11 Tris-HCl to NaOH.  The Tris-HCl reagent neutralizes the 
extracted DNA in preparation for PCR.  Specimens were microcentrifuged to pellet 
debris, and 1-5 μL of the supernatant was used for PCR in a total reaction volume of 25 
μL.   PCR was performed using 10X PCR Buffer, 2.5mM dNTPs, 5μM each of the 
appropriate forward and reverse primers, molecular grade water, and Taq Polymerase 
diluted to 1:8 with enzyme diluents.  The DNA Engine Tetrad thermocycler made by MJ 
Research was used for cycling the PCR reactions. 
 
3.1.5 Microinjections 
 The microinjection system used consisted of a Nikon® SMZ645 stereo 
microscope, a three-dimensional mechanical micromanipulator with micropipette holder 
made by the Narishige Group, and an automatic pressure regulator, model PLI-100 Basic 
Pico-Injector by Harvard Apparatus.  The pressurized injector permits small liquid 
volumes to be delivered precisely through the micropipettes.  Micropipettes, or needles, 
were made from fire-polished borosilicate glass capillaries made by Sutter Instrument 
with an outer diameter (O.D.) of 1.0 mm, an inner diameter (I.D.) of 0.75 mm, and a 




 Microinjection plate molds were made with Seakem® LE agarose by Lonza at 
1.2% in 1X E3 water (deionized water with 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4) using a TU-1 microinjection mold by Adaptive Science Tools.  Molds 
were made in a 100 mm by 20 mm polystyrene petri dish.  Injection volumes were 
calibrated using an eyepiece graticule where five tick marks viewed through a 5X 
objective corresponds to a diameter of 100 μm and a volume of 520 picoliters (pL).  
Injection of DNA concentrations higher than 0.1 mg per mL is toxic to the embryo and 
causes higher lethality (XU 1999; XU et al. 2008).  520 pL of mixture containing 
expression clone DNA and transposase cRNA were co-injected into embryos at a final 
concentration of 20 ng per μL.  Phenol red dye, at a final concentration of 0.0625%, was 
added to the injection mixture to help visualize the material. 
 
3.1.6 Fluorescent Microscopy 
 Detection of enhanced green fluorescent protein (EGFP), Discosoma red 
fluorescent protein (DsRed), and tandem-dimer Tomato (tdTomato) fluorescent protein 
was accomplished using a fluorescent microscope.   Excitation of fluorescent molecules 
is achieved with an ultraviolet (UV) light source.  Fluorescent molecules absorb the UV 
light at a specific wavelength and emit the light at a longer wavelength [Table 3]. 
 
3.2 Gateway Cloning Technology 
 Gateway® Cloning Technology by InvitrogenTM is based on the site-specific 
recombination system used by the lambda (λ) bacteriophage to integrate into and excise 
from the E.coli chromosome.  The λ phage enzyme Integrase (Int) and the E. coli 
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Table 3: Excitation and Emission Wavelengths of Specified Fluorescent Proteins 










EGFP 488 507 Green 
DsRed 558 583 Red/Orange 
tdTomato 554 581 Red/Orange 
 
 
Integration Host Factor (IHF) protein catalyze integration, while an additional λ phage 
enzyme, Excisionase (Xis), is required for excision.  The enzymes bind specifically to 
recombination sites or attachment sites, denoted as att sites: attB for bacterial and attP for 
phage.  The recombination sites used in Gateway® Cloning are designed with several 
point mutations in contrast to wild-type sites to confer an even higher specificity 
(INVITROGENTM 2006; INVITROGENTM 2010a; INVITROGENTM 2010b). 
 To generate an expression vector that contains a transgene and a reporter gene, the 
transgene must be amplified by PCR with primers containing appropriate attB sites.  The 
PCR product and a donor vector (pDONR) containing attP sites and selection genes are 
then combined with BP ClonaseTM II enzyme mix to generate an entry clone or entry 
plasmid (pENTR) [Figure 1].  BP ClonaseTM II enzyme mix contains Integrase and 
Integration Host Factor proteins to catalyze the recombination between attB and attP sites 
to create attL and attR sites within the entry clone.  Two to six entry clones can be made 
in separate BP recombination reactions depending on the design of the final expression 




Figure 1. Gateway BP Reaction.  KANR=kanamycin resistance gene. 
 
 
The entry clones are then combined with a destination vector (pDEST) and with LR 
ClonaseTM II enzyme mix to produce the expression clone.   The LR ClonaseTM II enzyme 
mix contains the Integrase, Integration Host Factor, and Excisionase proteins.  The 
destination vector contains a selective ccdB gene and a selective chloramphenicol 
resistance (CmR) gene.  The ccdB protein is toxic to most E. coli and will be produced in 
bacteria containing destination vectors that do not successfully undergo the LR 
recombination reaction.  Initially, before the production of the ccdB protein, these 
bacteria colonies will be capable of growing on media with chloramphenicol and can be 
excluded.   Additionally, the destination vector has been engineered to contain Tol2 sites, 
discussed in Section 3.2, to facilitate transposition into the host genome (INVITROGENTM 
2006; INVITROGENTM 2010a; INVITROGENTM 2010b).  A basic 2-cassette expression clone 
has a 5′ element (5E) and a 3′ element (3E) [Figure 2].  The 3-cassette expression clone 

































3.3 Tol2 Transposition System 
 The Tol2 sites present in the destination vector originate from the Tol2 gene 
identified in the genome of the medaka fish, Oryzias latipes, a fresh water teleost (KOGA 
et al. 1996).  To date, Tol2 is the only autonomously-active transposable element found 
in a vertebrate genome.  The Tol2 gene, approximately 4.7 kilobases (kb) in length, 
encodes a transposase protein that is autonomously active, meaning the protein is capable 
of catalyzing the excision and integration reaction by itself (KAWAKAMI et al. 1998; 
KAWAKAMI et al. 2004a; KAWAKAMI and NODA 2004; HAMLET et al. 2006; KAWAKAMI 
2007; SATO et al. 2007).  Tol2 transgenesis in zebrafish is accomplished by 
microinjecting a transposon-donor plasmid, such as the final expression clone, along with 
synthetic transposase messenger RNA (mRNA) into one-cell stage embryos.  Synthetic 
transposase mRNA or complementary RNA (cRNA) must be co-injected with the 
expression clone because a significant portion of the transposase coding region is not 
included in the donor plasmid.  The transposon-donor plasmid just provides the non-
autonomous, cis-recognition sequences necessary for transposition.  The minimal cis-
sequences required for transposition are 200 base pairs (bp) from the 5′ end and 150 bp 
from the 3′ end of the Tol2 gene (URASAKI et al. 2006).  The abundance of translation 
proteins in the embryo will generate transposase protein from the synthetic mRNA.   The 
transposase will then carry out the excision and integration of the transgene.     
  
3.4 Recombineering BAC Clones in Escherichia coli 
 Bacterial artificial chromosomes (BACs) are carriers or vectors of DNA 
sequences that are capable of entering bacteria for subsequent molecular cloning.  BAC 
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vectors are derived from the fertility (F) plasmid of certain bacteria and possess necessary 
replication and selection tools.  BAC vectors can accommodate long lengths of genomic 
DNA up to 350 kilobases, a characteristic that makes BAC vector great tools for genetic 
research.  Methods have been developed for modifying the DNA cloned into BAC using 
homologous and site-specific recombination within Escherichia coli.  This approach is 
highly efficient and less time-consuming for introducing linear DNA into BAC clones.  
Utilizing recombination within E. coli to modify DNA cloned into BACs is referred to as 
recombineering. 
 The recombineering method employed for this project uses a modified E. coli 
strain, EL250 cells, which possess an intentionally defective lambda (λ) prophage.  This λ 
prophage provides the genes necessary for homologous and site-specific recombination 
within the EL250 cells.  The λ red, exo, and bet genes provide homologous 
recombination enzymes.  A genetically engineered version of the wild-type flp gene 
provides a site-specific recombination enzyme with high recombination efficiency. 
 Used for homologous recombination, the λ gam gene provides a protein that 
inhibits the E. coli RecBCD nuclease from destroying electroporated linear DNA.  Exo, 
bet, and gam genes are under the control of the PL operon, which is controlled by a 
temperature-sensitive λ repressor protein, cI857.  At 32°C, the repressor protein blocks PL 
operon activity.  When the EL250 bacteria are heated to 42°C, the repressor no longer 
inhibits the PL operon and exo, bet, and gam recombination proteins are expressed (LEE et 
al. 2001; LIU et al. 2003). 
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 The flpe gene is derived from a 2 μm plasmid of the Saccharomyces cerevisiae 
yeast.  The flippase (Flpe) protein will specifically recombine sequences between 
Flippase Recognition Target (FRT) sites.  The FRT site sequence is:  
5′-GAAGTTCCTATTCtctagaaaGTATAGGAACTTC-3′, where lower case indicates the 
asymmetric core region.  The asymmetric core and the placement of the FRT sites dictate 
whether the intervening DNA will be excised or inverted.  Excision will occur when the 


















Intervening DNA such as 
AmpR gene. 
+ Flp recombinase 
FRT 
Figure 4.  Flp/FRT Recombination.   




 Lipofection or liposomal transfection is a technique for introducing genetic 
material such as expression clones into cultured cells by means of liposomes.  
Synthesized cationic lipids form liposomes that interact with anionic DNA.  The DNA-
containing liposomes fuse with the plasma membrane of cultured cells, resulting in 
delivery and expression of DNA within the cells (FELGNER et al. 1987; MOK and CULLIS 
1997).  To test the inducibility of the two-cassette expression clone, cultured Jurkat cells, 
a human leukemia T cell line, were lipofected with the expression clone using the 
TransIT®-LT1 Transfection Reagent by Mirus Bio LLC.  Following lipofection, Jurkat 
cells were stimulated with PMA (phorbol 12-myristate 13-acetate) and Ionomycin from 
Streptomyces conglobatus (Sigma Aldrich®).  The TransIT®-LT1 Transfection Reagent 
has been used successfully in several studies, including a luciferase reporter assay that 
helped characterize a novel regulatory pathway involved in an NF-кB-mediated 









4.1 Approach 1: Two-Cassette Design 
4.1.1 Two-Cassette Expression Clone 
 The Gateway® cloning system by Invitrogen was used to generate an expression 
clone containing the basal carp beta-actin (β-actin) promoter, the enhanced green 
fluorescent protein (EGFP) gene, and the human TNFα (hTNFα) enhancer donated by Dr. 
Anne Goldfeld, MD (GOLDFELD et al. 1990) [Figure 5].  The hTNFα enhancer sequence 







A human enhancer was chosen because the zebrafish TNFα (zTNFα) promoter has not 
been characterized functionally. Thus, it is unclear where exactly the important 
regulatory elements are located.  A previous attempt, using a 5.0 kilobase sequence 
located upstream of the zebrafish TNFα gene, did not produce an inducible expression 
model; data not published (REDD 2007) [Figure 6]. 
 
  






Figure 6. Putative Enhancers for zTNFα.  UCSC Genome Browser: Zebrafish March 
2006 Assembly (Zv6/danRer4).  The image shows a view of chromosome 19 at position 
22,099,500-22,142,000 approximately. http://www.genome.ucsc.edu (KENT et al. 2002). 
  
 Additionally, although genome database searches reveal conserved putative 
enhancers of the TNFα gene between sequenced teleosts, such sequence conservation is 
not seen between mammals and teleosts.  In this scenario, the options are to use either 
regulatory elements from a different species that drives TNFα expression or to use a 
bacterial artificial chromosome (BAC) containing the entire zebrafish TNFα gene that 
should provide the majority of cis-regulatory elements for expression of a transgene. 









Established mammalian enhancers have been used successfully in zebrafish to induce 
expression of reporter genes in a tissue-specific manner (FISHER et al. 2006). Therefore, 
we first chose the well-characterized human TNFα (hTNFα) enhancer in conjunction 
with the EGFP reporter gene under control of basal carp β-actin promoter, abbreviated as 
bas or bactin, to drive expression of the EGFP reporter gene in zebrafish cells that are 
expressing zTNFα (CALDOVIC and HACKETT 1995). 
 The hTNFα enhancer was provided in the pOCAT vector that contains an 
ampicillin resistance gene (GOLDFELD et al. 1990).  Plasmid DNA was extracted using 
the Wizard® Plus Miniprep DNA Purification System by Promega.  PCR amplification of 
the hTNFα enhancer was accomplished using Advantage® Taq polymerase, the CA55S 
thermocycler protocol [Appendix D], and primers designed to contain the appropriate 
attB sites as well as a few sequences from the 5′- and 3′-end of the hTNFα enhancer (attB 
hTNFα enhancer forward and reverse primers) [Appendix C].  PCR gel bands were 
excised, extracted using Qiagen’s QIAquick® Gel Extraction Kit, and sequenced using a 
hTNFα enhancer sequencing primer [Appendix C].  The attB-flanked hTNFα enhancer 
cDNA was cloned into the pDONR P4-P1R vector by Invitrogen using BP ClonaseTM II 
enzyme mix to generate a 5′ Entry clone.  The 5′ Entry clone was transformed into DH5α 
competent E. coli cells which were subsequently grown in S.O.C. media; E. coli cells and 
media are made by InvitrogenTM by Life TechnologiesTM.  Selection of transformed 
bacteria was performed using Lysogeny broth (LB) media with 50 μg per mL of 
Kanamycin.  Twenty colonies were chosen for PCR screening using M13 forward and 
reverse primers that amplify the region where hTNFα enhancer incorporates via att 
recombination sites [Appendix C].  The CA55S thermocycler protocol was used for this 
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PCR amplification [Appendix D].  Two of the twenty colonies were positive by PCR and 
were subsequently subcultured, followed by DNA extraction using Qiagen’s QIAprep® 
Spin Miniprep Kit.  Extracted DNA was sequenced using the same M13 forward and 
reverse primers.  Contig analysis of the sequencing results demonstrated the presence of 
the hTNFα enhancer within the pDONR P4-P1R vector flanked by appropriate attR1 and 
attL4 sites. 
 The pENTRbasEGFP vector provided by Dr. N.D. Lawson’s laboratory at the 
University of Massachusetts was used as the 3′ Entry clone in this two-cassette design.  
The 3′ and 5′ ENTRY clones were combined with the destination vector pTolR4R2pA, 
also provided by Dr. Lawson’s laboratory, in an LR ClonaseTM II enzyme reaction mix to 
produce the final expression clone (VILLEFRANC et al. 2007).  The expression clone was 
transformed into DH5α competent E. coli cells which were subsequently grown in S.O.C. 
media.  Positive selection of transformed bacteria was performed using LB media with 50 
μg per mL of ampicillin.  Fourteen colonies grew on the selection media and were by 
screened by PCR for the presence of Tol2 and EGFP.  DNA was amplified using a 
modified CA55S thermocycler protocol [Appendix D] and by using the forward primer 
Tol2_F, designed to anneal at the Tol2 site adjacent to the 5′ entry cassette, and the 
reverse primer EGFP_R, designed to anneal at the 3′-end of the EGFP gene [Appendix 
C].  All 14 colonies were positive by PCR.  All of the colonies were subcultured, 
followed by DNA extraction using Qiagen’s QIAprep® Spin Miniprep Kit.  Three 
positive colonies were chosen for sequencing confirmation using primers that anneal to 
the hTNFα enhancer (Expr_F), the EGFP gene (Expr_R), and the flanking Tol2 sites 
(Tol2_F; Tol2_R_b) [Appendix C].  Contig analysis of the sequencing results 
35 
 
demonstrated the presence of a correct expression clone containing the hTNFα enhancer 
element, the basal carp beta-actin promoter, and the EGFP gene within the pTolR4R2pA 
vector. 
 
4.1.2 Lipofection and Drug Induction of Jurkat Cells 
 Prior to microinjection, the inducibility of the two-cassette expression clone was 
tested by lipofection into the human leukemia T cell line Jurkat using the TransIT®-LT1 
Transfection Reagent by Mirus Bio LLC followed by stimulation with PMA (phorbol 12-
myristate 13-acetate) and Ionomycin from Streptomyces conglobatus, supplied by Sigma 
Aldrich®.  PMA and Ionomycin are known to activate protein kinase C which targets the 
transcription factors NF-кB and AP-1 (SAITOH and DOBKINS 1986; CHATILA et al. 1989; 
ISAKOV and ALTMAN 2002).  Also, PMA induction of TNFα expression has been shown 
in T and B cell lines; specifically, HUT78, P30, HPB-ALL, and Jurkat T cell lines and 
the Raji B cell line (GOLDFELD et al. 1991).  Jurkat cells were cultured in RMPI 1640 
medium with 10X Fetal Bovine Serum and 1X Penicillin and Streptomycin (InvitrogenTM 
by Life TechnologiesTM).  Jurkat cells were grown overnight in a T75 culture flask at 
37°C and 5% CO2 incubator.   Cells were quantitated with a hemocytometer and then 
replated into a 6-well cell-culture plate at a concentration of 1x106 cells per mL.   
 The Jurkat cells in wells 4-6 were lipofected for five hours.  Jurkat cells in wells 
1-3 were not lipofected [Figure7].  Additional culture medium was added to bring the 
total volume of each well to 3 mL.  Subsequently, the lipofected cells in wells 5 and 6 
were stimulated with PMA and Ionomycin.  Concentrations of PMA and Ionomycin were 



































  Figure 7.  Lipofection and Drug Stimulation Assay.  6-well plate with 
  Jurkat cells at a concentration of 1x106 cells per mL in each well. 
 
The final concentrations of PMA and Ionomycin in well 5 were 50ng per mL and 
0.25μM, respectively.  The final concentrations of PMA and Ionomycin in well 6 were 
250.9 ng per mL and 0.125μM, respectively. 
 Cells were examined for EGFP fluorescence prior to stimulation, at 7.5 hours 
poststimulation, 24 hours poststimulation, and 48 hours poststimulation.  “Leakiness,” 
basal transgene expression in the absence of stimulation, was assessed in well 4.  
Fluorescent cells were quantitated between 49 and 52 hours poststimulation.  Only cells 
showing bright green fluorescence were counted; cells showing faint green fluorescence 
were not counted [Figure 8].  Jurkat cells lipofected with the two-cassette expression 
clone demonstrated dose-dependent fluorescence [Figure 9].  Bright fluorescent cells 
were attributed to successful enhancer-driven expression of EGFP.  The faint 



















Well 4 Well 5 Well 6
Number of GFP positive Jurkat cells
Number of GFP positive Jurkat cells
Figure 9.  Graphical Chart Representation of Quantitated Fluorescent Cells per Well. 
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4.1.3 Microinjection and PCR Screening 
 Between November 2008 and February 2009, 382 zebrafish embryos obtained 
from the *AB wild-type strain were injected at the one-cell stage with of the two-cassette 
expression clone containing the hTNFα enhancer, the carp beta-actin basal promoter, and 
the enhanced green fluorescent protein gene, along with transposase cRNA and phenol 
red dye.  DNA and transposase cRNA were at a final concentration of 20 ng per μL, 
while phenol red dye was at a final concentration of 0.0625%.  Approximately 271 of the 
382 injected embryos survived to adulthood.  Sperm were collected from 74 males and 
fertilized eggs from 17 females.  Females were bred with *AB wild-type males to obtain 
embryos at 24 hours postfertilization (hpf) which have a greater amount of DNA 
compared to a single-celled egg.  DNA was extracted from the sperm and embryos using 
the modified HotSHOT protocol and screened by PCR for the presence of the enhanced 
green fluorescent protein (EGFP) gene using EGFP_F and EGFP_R primers and the 
EGFP thermocycler protocol [Appendix C and D].  Genomic DNA from the tail fin of a 
wild-type zebrafish, most often *AB wild-type, was used as a negative control.  The 
pENTRbasEGFP vector was used as the positive control.  A tube of PCR reagents 
without any DNA template served as a negative reagent control.  A separate PCR 
amplification was performed simultaneously to provide a quality control check of the 
DNA extraction and of Taq polymerase performance.  This PCR reaction using the EGFP 
thermocycler protocol confirms the presence of DNA using primers that target a marker 
on zebrafish chromosome eight, named Z60737 [Appendix C].  Unfortunately, the germ-
line cells from all 91 zebrafish were negative for the EGFP gene.  This prompted the 
design of a new three-cassette expression clone. 
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4.2 Approach 2: Three-Cassette Design 
4.2.1 Three-Cassette Expression Clone 
 A three-cassette expression clone was created to introduce a second fluorescent 
reporter protein gene, Discosoma red fluorescent protein (DsRed), under control of the 
Xenopus laevis γ-crystallin promoter, Cry (SMOLICH et al. 1993; OFFIELD et al. 2000; 
YARBROUGH et al. 2001).  Crystallins are expressed at high levels in the lens of the eye.  
As a result, the γ-crystallin promoter makes DsRed expression lens-specific.  Addition of 
this lens-specific fluorescent protein facilitates preselection of putative transgenic 
founders.  The presence of red fluorescence in the lens should be associated with a higher 
frequency of expression clone transgenesis into germ-line cells (VOPALENSKY et al. 
2010).  Therefore, only zebrafish with red fluorescent lenses will be further screened for 
germ-line transgenesis.   
 An ENTRY vector containing the CryDsRed insert was obtained from Dr. H. J. 
Yost’s laboratory at the University of Utah.  The CryDsRed vector is the 3′ ENTRY 
clone in this design.  The 5′ ENTRY clone is the same vector used in the two-cassette 
design.  The pENTRbasEGFP vector becomes the middle entry clone for this three-
cassette expression clone design [Figure 10].   




Figure 10.  Three-cassette Expression Clone for Second Approach. 
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enzyme reaction with the destination vector pDEST Tol2pA, which contains the 
appropriate att recombination sites for generating a three-cassette expression clone 
(KWAN et al. 2007).  The destination vector pDEST Tol2pA is provided by Dr. N.D. 
Lawson’s laboratory at the University of Massachusetts.  The final expression clone was 
transformed into Library Efficiency® DH5αTM Competent E. coli cells which were 
subsequently grown in S.O.C. media.  Positive selection of transformed bacteria was 
performed using LB media with 50 μg per mL of ampicillin.  Thirty colonies were chosen 
for additional concurrent selection using LB media with 50 μg per mL of ampicillin for 
positive selection, and LB media with 12.5 μg per mL of chloramphenicol for negative 
selection.  The 30 colonies were screened by two separate PCR amplifications using 
different sets of primers.  The first amplification was accomplished with expression clone 
primers and the EXPR thermocycler protocol; Expr_F anneals to the hTNFα enhancer 
and Expr_R anneals to the EGFP gene.  The second amplification was performed using 
the DSRED thermocycler protocol and using primers designed to anneal to the DsRed 
gene (DsRed_F; DsRed_R) [Appendix C and D].  Twenty-nine of thirty colonies were 
positive for the DsRed gene, the hTNFα enhancer, and the EGFP gene.  Three colonies 
were chosen for subculturing and DNA extraction using Qiagen’s QIAprep® Spin 
Miniprep Kit.  DNA from the three colonies was sequenced to confirm the presence of 
the expression clone using a reverse primer (ME_Rev) designed to anneal to the middle 
entry cassette and amplify the middle and 5′ entry cassettes, and a reverse primer 
(3E_Rev) designed to anneal to the crystalline promoter of the 3′ entry cassette and 




4.2.2 Microinjection and PCR Screening of 
Three-Cassette Expression Clone 
 Between November and December of 2009, approximately 1,040 zebrafish 
embryos obtained from the *AB wild-type strain were injected at the one-cell stage with 
520 pL of the three-cassette expression clone along with transposase cRNA and phenol 
red dye.  DNA and transposase cRNA were at a final concentration of 20 ng per μL, and 
phenol red dye at a final concentration of 0.0625%.  Approximately 938 of 1,040 injected 
embryos survived to adulthood and were screened by fluorescent microscopy for the 
presence of red fluorescent lenses.  Fourteen fish were positive for lens-specific red 
fluorescence: five fish with both eyes, and nine fish with only one eye, a partial eye(s), or 
a possible gill location [Figure 11]. 
 Six of the fourteen DsRed-positive fish died before they were sexually mature for 
germ-line PCR screening.  Sperm and fertilized eggs from seven of the eight remaining 
DsRed-positive fish, three males and four females, were screened by PCR for the 
presence of the EGFP gene using EGFP_F and EGFP_R primers and the EGFP 
thermocycler protocol [Appendix C and D].   Genomic DNA from the tail fin of a wild-
type zebrafish served as a negative control, the pENTRbasEGFP vector served as the 
positive control, and a tube of PCR reagents without any DNA template served as a 
negative reagent control.  A separate PCR amplification was performed simultaneously to 
provide a quality control check of the DNA extraction and of Taq polymerase 
performance.  This PCR reaction using the EGFP thermocycler protocol confirms the 
presence of DNA using primers that target a marker on zebrafish chromosome eight, 

















 All seven were negative for the EGFP gene.  Embryos from the four DsRed-positive 
females were subsequently screened further by PCR for the presence of the hTNFα 
enhancer using hTNFαEnh_F and hTNFαEnh_R primers and the EGFP thermocycler 
protocol and for the presence of the DsRed gene using DsRed_F and DsRed_R primers 
and the DSRED thermocycler protocol [Appendix C and D].  In these PCR assays, the 3-
cassette expression clone and the entry clone containing the CryDsRed cassette were used 
as positive controls.  The fertilized eggs from all four of the females were negative for the 
hTNFα enhancer and for the DsRed gene. 
 
 
  A                                     B 
 
  C                                     D 
Figure 11. DsRed Fluorescent Eye Lenses. 
 
A,B: Right and Left eye lens showing DsRed 
fluorescence from a putative male founder. 
C: Left eye lens showing DsRed fluorescence 
from another putative male founder. 
D: Faint DsRed fluorescence from eye lens of 
a putative female founder. 
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4.3 Approach 3: BAC Expression Clone 
4.3.1 Recombineering in E. coli 
 A bacterial artificial chromosome (BAC) clone (locus: BX469886; clone CH211-
127D20) was obtained from http://bacpac.chori.org. This BAC clone contains the entire 
zebrafish TNFα (zTNFα) gene, ~6.0 kb of additional upstream sequence, ~140 kb 
downstream sequence, and a chloramphenicol (Cm) resistance gene.  Dr. Jindong Wang, 
MD, PhD performed all of the steps necessary to generate the retro-fitted BAC 
expression clone.  For further details regarding the construction of the BAC expression 
clone that are not provided in this thesis, direct questions to Dr. Jindong Wang, MD, 
PhD.  Microinjection of the BAC expression clone and subsequent screening were 
performed by Danielle Elsberry.   
 The BAC clone was received in DH10 Escherichia coli cells which were cultured 
and BAC DNA was extracted.  BAC DNA was then electroporated into EL250 E. coli 
followed by selection with chloramphenicol (Cm).  A targeting cassette was created for 
electroporation into the EL250 bacteria containing the CH211-127D20 BAC DNA.  This 
initial targeting cassette was cloned into a pCR-XL-TOPO® vector by InvitrogenTM and 




Figure 12.  First Targeting Cassette for Recombineering. 
 
Linker tdTomato FRT FRT AmpR R. ARM L. ARM 
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 Amplification primers were designed to add 50 bp flanking sequences onto the 
targeting cassette which are homologous to the BAC vector, specifically, 50 bp upstream 
and 50 bp downstream of the zTNFα stop codon, referred to as the left arm (L. ARM) and 
the right arm (R. ARM).  Additionally, the left primer was designed to add a 21 bp linker 
sequence following the left arm which replaces the zTNFα stop codon and links the 
zTNFα and tdTomato genes creating a zTNFα:tdTomato transgene.  With this design, 
translation of the fluorescent tdTomato protein will be in-frame with the zTNFα protein, 
thereby providing a visual indicator of zTNFα expression.  The linker sequence also 
contributes to independent folding of the two proteins to preserve their function (OOI et 
al. 2006).   
 EL250 E. coli with the CH211-127D20 BAC DNA were heated to 42°C for 15 
minutes to induce expression of the recombination genes.  Then the linear DNA or 
targeting cassette was electroporated into the EL250 cells.  The linear DNA undergoes 
homologous recombination to be added into the CH211-127D20 BAC DNA [Figure 13]   
(LEE et al. 2001; LIU et al. 2003).  Bacteria were then grown on double selection media 
containing ampicillin and chloramphenicol. 
 The selection marker, ampicillin resistance gene (AmpR), introduced by the first 
targeting cassette into the CH211-127D20 BAC DNA is located in the 3′ untranslated 
region of the fusion protein, and has the potential to interfere with transcription and 
translation.  Site-specific recombination by the Flp protein will excise the AmpR gene.  
The FRT sites in the initial targeting cassette were placed in the same orientation to 
facilitate the excision.  Expression of the flpe enzyme within EL250 E. coli is inducible 





Figure 13.   Recombineering Reaction of First Targeting Cassette.  Adapted from  
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The bacterial culture was incubated with the arabinose for one hour to ensure removal of 
the AmpR gene.  Colonies were then selected by positive growth on chloramphenicol 
media and by negative growth on ampicillin media. 
 The final modification made to the CH211-127D20 BAC vector was the addition 
of Tol2 sites to facilitate the upcoming transposase-mediated integration into zebrafish 
genome.  A second targeting cassette of linear DNA was generated using primers 
designed to add 50 bp flanking sequences onto the targeting cassette which are 
homologous to the BAC clone, specifically, 50 bp upstream and 50 bp downstream of 
CmR gene.  The linear DNA is also designed to introduce a selection marker, AmpR gene, 
and the minimal Tol2 cis-sequences in an inverted orientation, referred to as iTol [Figure 
14] (SUSTER et al. 2009).   
 The EL250 E. coli were heated to 42°C to induce expression of the recombination 
genes exo, bet, and gam.  The second targeting cassette containing the Tol2 sites adjacent 
to an AmpR selection marker is electroporated in the EL250 E. coli cells and integrates by 
homologous recombination.  Correctly modified colonies are selected by growth on 
ampicillin media.  The final BAC vector includes the zTNFα:tdTomato transgene as well 
as the necessary Tol2 sites [Figure 15].  The final BAC expression clone is referred to as 






































AmpR L. Arm R. Arm 









Figure 14. Second Targeting Cassette to Introduce Tol2 Sites. 
                  Adapted from (SUSTER et al. 2009). 
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4.3.2 Microinjection and PCR Screening of BAC Expression Clone 
 During December 2009 and March 2010, one-cell stage zebrafish embryos 
obtained from the *AB wild-type strain were injected with 520 pL of the retro-fitted BAC 
expression clone and the CryDsRed vector.  The combined final DNA concentration of 
BAC expression clone and CryDsRed vector was 20 ng per μL.  The injection mixture 
also contained transposase cRNA at a final concentration of 20 ng per μL and phenol red 
dye at 0.0625%.  Transgenesis of the co-injected CryDsRed vector provides a means for 
preselecting putative transgenic founders; successful incorporation and expression of 
DsRed in the lens should be associated with a higher frequency of BAC clone 
transgenesis into germ-line cells (VOPALENSKY et al. 2010).  Approximately 722 
zebrafish embryos were injected with the retro-fitted BAC clone and the CryDsRed 
vector.  Approximately 596 to 599 embryos survived to the juvenile stage and were 
screened by fluorescent microscopy for the presence of red fluorescent lenses.  Sixty-two 
juveniles from the 722 injected embryos had DsRed-positive lenses, a transgenesis rate of 
8.6%.  Varying degrees of red fluorescence was observed.  For example, red fluorescence 
could be seen emitting from 80% of the lens or emitting only as pinpoints within the lens.  
Some fish had higher fluorescence in one eye compared to their other eye or fluorescence 
in one eye only.  Two fish that had pinpoint red fluorescence in the head region, not in 
the lens, were also kept for further screening.  Fifty-eight of the sixty-two DsRed-positive 
fish survived into adulthood for further screening.   
 To date, sperm and fertilized eggs from 45 DsRed-positive zebrafish, 36 males 
and 9 females, have been screened by PCR for the presence of the zTNFα:tdTomato 
transgene.  Primers were designed to amplify from the 3′-end of the zTNFα gene into the 
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linker DNA sequence (zTNFaTom_F) and to amplify from the 5′-end of the tdTomato 
gene (zTNFaTom_R) using the ZTNF thermocycler protocol [Appendix C and D].  
Therefore, the PCR product is unique to the BAC vector transgene and not indicative of 
native zTNFα.  Genomic DNA from the tail fin of wild-type zebrafish served as a 
negative control, BAC clone DNA served as the positive control, and a tube of PCR 
reagents without any DNA template served as a negative reagent control.  A separate 
PCR amplification was performed simultaneously to provide a quality control check of 
the DNA extraction and of Taq polymerase performance.  This PCR reaction using the 
EGFP thermocycler protocol confirms the presence of DNA using primers that target a 
marker on zebrafish chromosome eight, named Z60737 [Appendix C].  Two males were 
sperm-positive for the BAC vector transgene [Figure 16].  Two positives out of 45 fish is 
a germ-line integration rate of 4.4%.  Seventeen DsRed-positive zebrafish remain that 
need their germ-line cells screened by PCR. 
 
4.3.3 Stimulation Assays and PCR Screening of F1 Embryos  
 The two sperm-positive F0 males for the BAC vector transgene were bred with 
*AB wild-type females as well as with DsRed-positive females not yet confirmed to be 
germ-line positive.  Due to mosaicism within the sperm, only a small percentage of the F1 
offspring will be positive for the BAC transgene.  The positive F1 offspring will be 
heterozygous, and a minimum of one positive F1 male and one positive F1 female must be 
isolated for subsequent in-crossing to produce homozygous F2 offspring.  Breeding of the 
two sperm-positive F0 males produced approximately 15 tanks of F1 larvae to be screened 




Figure 16.  Gel Electrophoresis of Sperm DNA.  DNA was amplified by PCR using 
primers that detect the zTNFα:tdTomato transgene.  Lane 1: 1Kb Plus DNA Ladder by 
Invitrogen used for sizing linear double-stranded DNA fragments.  The ladder contains 
20 reference bands ranging in size from 100 bp to 12,000 bp.  Lane 2: Positive control; 
BAC expression clone DNA with expected base pair size of 376.  Lane 3: Negative 
control; genomic DNA from the tail fin clipping of a wild-type zebrafish.  Lane 4:  F0 
sperm DNA that is positive for the zTNFα:tdTomato transgene.  Lane 5-11: F0 sperm 
DNA that is negative for the transgene.  Lane 12:  Reagent control.  Please note that the 
bands seen below the 100 bp reference band are primer dimers. 
 
   
 To date, DNA has been extracted from the tail fin clippings of 101 F1 zebrafish 
using the modified HotSHOT protocol.  The same primer set, zTNFaTom_F and 
zTNFaTom_R, and ZTNF thermocycler protocol that was used to detect the presence of 
the BAC vector transgene in F0 germ-line cells was employed for screening the tail fin 
DNA of the F1 larvae [Appendix C and D].  Genomic DNA from the tail fin of wild-type 
zebrafish served as a negative control, BAC clone DNA served as the positive control, 
and a tube of PCR reagents without any DNA template served as a negative reagent 
control.  A separate PCR amplification was performed simultaneously to provide a 
quality control check of the DNA extraction and of Taq polymerase performance.  This 
PCR reaction using the EGFP thermocycler protocol confirms the presence of DNA using 
primers that target a marker on zebrafish chromosome eight, named Z60737 [Appendix 













C].  To date, DNA from one F1 female is positive for the BAC vector transgene [Figure 
17].  One positive heterozygote in 101 F1 zebrafish indicates that a low percentage of the 
F0 sperm is transgenic positive. PCR screening of the remaining F1 zebrafish will 
continue with the aim of identifying a positive F1 male to in-cross with the positive F1 
female.  In the meantime, the positive heterozygous F1 female will be bred with a wild-
type male to produce F2 embryos.  Fifty percent of these F2 embryos will be positive for 




Figure 17.  Gel Electrophoresis of Tail Fin DNA.  DNA was amplified by PCR using 
primers that detect the zTNFα:tdTomato transgene.  Lane 1: 1Kb Plus DNA Ladder by 
Invitrogen used for sizing linear double-stranded DNA fragments.  The ladder contains 
20 reference bands ranging in size from 100 bp to 12,000 bp.  Lane 2: Negative control; 
genomic DNA from the tail fin clipping of a wild-type zebrafish.  Lane 3: Positive 
control; BAC expression clone DNA. Expected base pair size of 376.  Lane 5-6:  F1 tail 
DNA, in duplicate from the same zebrafish, that is positive for the zTNFα:tdTomato 
transgene.  Lane 4 and 7-10: F1 tail DNA that is negative for the transgene. Lane 38 (not 
shown): Reagent control.  Please note that the bands seen below the 100 bp reference 
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 In addition to creating F1 larvae for PCR screening, separate F1 embryo 
populations were generated for experiment purposes only.  These F1 embryo populations 
were stimulated either with PMA and Ionomycin or injected with E. coli to see if any 
fluorescence could be observed.  F1 embryo populations were stimulated with 100 ng per 
mL of PMA and 0.10 μM of Ionomycin.  These optimal concentrations of PMA and 
Ionomycin were determined by a separate toxicity experiment performed by Dr. Nikolaus 
Trede, MD, PhD, on wild-type embryos at two days postfertilization (dpf).  PMA and 
Ionomycin were added to the water without de-chorionating the embryos.  The 100 ng 
per mL of PMA and 0.10 μM of Ionomycin caused death in only 10% of the embryos at 
24 hours poststimulation, whereas 250 ng per mL of PMA and 0.25 μM of Ionomycin 
caused death in 50% of embryos, and 500 ng per mL of PMA and 0.50 μM of Ionomycin 
caused death in 90% of the embryos.   
 One-hundred and thirty-five F1 embryos from male founder A1 and ninety F1 
embryos from male founder A2 were stimulated with PMA and Ionomycin.  In addition, 
42 F1 embryos from male founder A1 and 25 F1 embryos from male founder A2 were not 
stimulated to serve as a negative control.  The F1 embryos were divided into three groups 
to be stimulated with 100 ng per mL of PMA and 0.10 μM of Ionomycin at three 
different time points: the first group at 24 hours postfertilization (hpf), the second group 
at 48 hpf, and the third group at 72 hpf.  Embryos at 24 and 48 hpf were not de-
chorionated.  The majority of embryos at 72 hpf had hatched from their chorion. 
Stimulated embryos were screened for tdTomato fluorescence at 1, 3, 6, 8, 24, 48, and 72 
hours poststimulation; no fluorescence was observed in any population at any designated 
time-point.  We concluded that the percentage of sperm that are positive for the BAC 
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vector must be low in both male founders.  Another possibility is that the chorion could 
have hindered diffusion of the drugs. 
 In addition to the PMA and Ionomycin stimulation assays, a population of F1 
embryos was injected with standard laboratory E. coli bacteria by Dr. Michael Redd, 
PhD.  Forty embryos at 24 hpf, twenty from each male founder, were anesthetized with 
tricaine and mounted in 1% low-melt agarose made with 1X E3 water.  Glass capillary 
needles that were attached to an automatic pressure-regulated injector were loaded with 
the bacteria.  Mounted embryos were injected with the bacteria at the end of the yolk sac 
just above the anus.  Embryos were observed for tdTomato fluorescence prior to 
injection, one hour postinjection, and six hours postinjection.  No fluorescence signal was 
visualized at any time-point.  Again, it was concluded that the percentage of sperm that 













5.1 Utility of the hTNFα Enhancer in Zebrafish 
 The utility of the hTNFα enhancer as an inducer of a fluorescent reporter protein 
in zebrafish has not yet been determined due to the lack of germ-line-positive founders 
(F0) from microinjections of either the two- or three-cassette design.  Failure to achieve 
germ-line positive zebrafish was due to technical difficulties with the microinjections and 
possibly because the human enhancer does not incorporate or function in zebrafish.  The 
injection volume of the two-cassette expression clone was calibrated incorrectly and 
likely caused the lack of transgenesis.  Injecting volumes greater than 1nL can cause the 
nucleus to burst or result in nonspecific deformities (XU 1999).  Although the injection 
volumes were calibrated correctly for the three-cassette expression clone and DsRed 
expression was observed in the lenses of some of the injected fish, this three-cassette 
clone also failed to incorporate into germ-line cells.  We reasoned that the single putative 
male founder with both eyes positive for lens-specific DsRed fluorescence would be 
germ-line positive for the expression clone.  However, this was not the case with this 
male or any other DsRed-positive zebrafish.  Incorporation of the expression clone into 
the genomes of the embryos must have occurred too late for transmission to germ-line 
cells.  It is also possible that the human source of the TNFα enhancer caused problems 
with transgenesis.  DsRed expression in only 14 of ~1,040 injected zebrafish translates to 





is much lower than reported transgenesis rates using the Tol2 transposition system 
(KAWAKAMI et al. 2004b; URASAKI et al. 2006).  Again, this low transgenesis rate is 
probably attributed to technical difficulties with the microinjections.   
   
5.2 Utility of the BAC Expression Clone 
 Until offspring with reliable transgenesis are obtained from positive F1 or F2 
zebrafish, the utility of the BAC expression clone cannot be assessed.  However, we are 
hopeful that the BAC expression clone will work and become a useful research tool for 
the following reasons.  1) The BAC expression clone introduces a gene that is native to 
the zebrafish, an advantage compared to artificially-designed or nonnative genes that can 
be recognized as foreign and become methylated.  2) TNFα is known to be expressed in 
several diseases; therefore, our transgenic model will be a useful tool to the scientific 
community for studying multiple diseases, including infection and autoimmune disorders.  
It is known that not all septic patients have detectable TNFα levels.  However, we will 
choose bacteria that do induce TNFα expression in infection studies using our transgenic 
model.  Also, baseline TNFα expression in humans has not been defined (VAN DER POLL 
and LOWRY 1995); therefore, only transgenics that demonstrate a low baseline level of 
TNFα expression will be chosen for TLR signaling assays.  3) Our transgenic BAC 
model contains 31 potential transcription factor or transcription coactivator binding sites 
for TNFα activation that have been characterized in other species.  An informatic search 
of sequence from 5.0 kilobases upstream, from the first exon, and from the first intron of 
the native zebrafish TNFα gene, identified these 31 potential binding sites including two 





.  The search was performed using TRANSFAC version 4.0 software at 
 and by applying the following 
settings: pair similarity to known sites-50%, matrix width in bp-12, minimum number of 
sites-5, minimum matrix conservation-75.  The Sp1 transcription factor is known to be 
involved in TNFα gene activation within mammalian T cell lines stimulated with virus or 
within B cells stimulated with LPS or Mycobacterium tuberculosis (FALVO et al. 2000; 
FALVO et al. 2010).  The NF-кB and Oct-1 binding sites located within the first intron of 
the zTNFα gene may be important sites where transcription factors can interact and 
cooperate with other factors bound to sites upstream and downstream of the transcription 
start site.  In mammals, the induction of TNF gene transcription by virus or LPS does not 
depend on NF-кB binding to the proximal promoter.  However, attainment of maximal 
TNF mRNA levels does involve an NF-кB postinduction mechanism that is not fully 
characterized (TSYTSYKOVA et al. 2007).  4) The BAC expression clone includes ~6.0 kb 
of additional upstream sequence and ~140 kb of downstream sequence to the zebrafish 
TNFα gene that may contain further regulatory elements, such as enhancer sequences, to 
possibly aid in TLR signaling and disease model studies.   
 
 5.3 Future Objectives and Proposed Alternatives 
 The main objective for future experiments is to finish the PCR screening of the 
remaining F1 offspring derived from the sperm-positive BAC clone males.  Identifying a 
heterozygous F1 female and F1 male will facilitate the generation of homozygous F2 
                                                 
2  NF-кB, nuclear factor-kappa B; AP-1, activator protein-1; CRE-BP1, cAMP-response element-binding 
protein-1; NF-1, nuclear factor-1; Sp1, specificity protein 1; Oct-1, octamer-binding protein 1; TBP, 
TATA-box binding protein. 
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offspring.  One hundred percent of the offspring from a homozygous zebrafish will have 
the transgene.  This facilitates the interpretation of experiments and obviates the need for 
genotyping.  These offspring are best-suited for the ultimate goal of studying TLR 
signaling and for determining compounds and genes that affect TNFα production through 
large-scale chemical and genetic screening.   
 We decided to abandon further embryo injections of the expression clones 
containing the hTNFα enhancer because the advantages of the BAC expression clone 
outweigh the possible advantages of the hTNFα enhancer clone.  The functionality of the 
hTNFα enhancer in zebrafish could be tested by transiently injecting embryos with the 
expression clone and with LPS to see if any green fluorescence is produced.  
Furthermore, it is possible that the fluorescence observed in drug-stimulated, lipofected 
Jurkat cells was not dose-dependent.  The number of Jurkat cells that produced EGFP 
fluorescence via the hTNFα enhancer could be attributed to better-quality lipofection 
isolated to a particular well.  Perhaps cells in one well received slightly more lipofection 
reagent than another well which resulted in the greater number of fluorescent cells.  The 
assay could be repeated with lipofection occurring in a larger, single culture dish before 
splitting the cells into a 6-well plate for drug stimulation.  This would increase the 
confidence of our conclusion that the fluorescence was dose-dependent. 
 One alternative to our approach would be using the genome of pufferfish, Fugu 
rubripes.  Although conservation of putative TNFα enhancers is not seen between 
mammals and teleosts, genome database searches comparing the pufferfish and zebrafish 
genomes do show conserved putative enhancers for the TNFα gene; data not shown.  
Characteristics of the Fugu genome offer several advantages for research.  The complete 
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genome of Fugu is only 400Megabases (Mb) as compared to 1700Mb in the zebrafish 
genome and 3000Mb in the human genome.  The smaller Fugu genome is attributed to 
highly-compressed intergenic and intronic sequences and a low amount of repeats.  The 
result is a gene density of 17% coding sequence in the Fugu genome compared to just 3% 
in the human genome.  The Fugu genome still contains necessary noncoding sequences, 
and the evolutionary distance between mammals and fish provides a high stringency for 
identifying conserved noncoding sequences (BRENNER et al. 1993; VENKATESH et al. 
2000; VENKATESH and YAP 2005).  All of these characteristics make the Fugu genome a 
good reference for more complex genomes and an easier genome to use in research.  A 
second alternative to our approach would be designing a fluorescent reporter system 
inducible by the expression of different cytokines such as interleukin-1 (IL-1), IL-12, or 









 HUMAN TLRS EXPRESSED ON THE CELL SURFACE 
 
Table 4:  Human TLRs (hTLRs) Expressed on the Cell Surface.  Data summarized from 







heterodimer Triacylated lipopeptides 
Gram-negative bacteria & 
Mycoplasma 
TLR2-TLR6 
heterodimer Diacylated lipopeptides 
Gram-positive bacteria & 
Mycoplasma 
TLR2 Lipopeptides Bacteria 
 Peptidoglycan (PG) & Lipoteichoic acid Gram-positive bacteria 
 Lipoarabinomannan Mycobacteria 
 Zymosan Fungi 
 tGPI-mucin Trypanosoma cruzi 
 Hemagglutinin protein Measles virus 
TLR4 Lipopolysaccharide (LPS) Gram-negative bacteria 
 Fusion (F) protein Respiratory syncytial virus (RSV) 
 Envelope (Env) protein Mouse mammary tumor virus (MMTV) 
 Pneumolysin Streptococcus pneumonia (Gram-positive) 
 Paclitaxel, a cytostatic drug Plant-derived 
TLR5 Flagellin Flagellated bacteria 






Extracellular Matrix (ECM) degradation 
products: biglycan, hyaluronic acid, versican, 
extradomain A of fibronectin, 
and surfactant protein A. 
Endogenous host molecule 
 High-mobility group box 1 (HMGB1) protein Endogenous host molecule 







HUMAN TLRS EXPRESSED IN INTRACELLULAR VESICLES 
 
Table 5:  Human TLRs (hTLRs) Expressed in Intracellular Vesicles.  Data summarized 












TLR3 dsRNA Produced during replication of ssRNA viruses 
 Genomic RNA Reoviruses 
 Polyinosinic-polycytidylic acid (poly(I:C)) Synthetic analog of dsRNA 
TLR7 ssRNA RNA viruses 
 Imidazoquinoline derivatives & guanine analogs Synthetic 
TLR8 ssRNA RNA viruses 
TLR9 
Unmethylated 2′-deoxyribo(cytidine-
phosphate-guanosine) (CpG) DNA 
motifs 
Bacteria & DNA viruses 
 Insoluble crystal hemozoin Plasmodium falciparum 







PCR PRIMER SEQUENCES 
 
Table 6: PCR Primer Sequences.  The sequence of attB sites are indicated in lower case. 
Primer Designation Sequence 
attB hTNFα enhancer Forward primer 5′- gggacaactttgtatagaaaagttgATG CTTGTGTGTCCCCAACTTTCCA -3′ 
attB hTNFα enhancer Reverse primer 
5′- ggggactgcttttttgtacaaacttgCGT 
CTGAGGGTTGTTTTCAGG -3′ 
hTNFα enhancer sequencing primer 5′- ATGCTTGTGTGTCCCCAACTT -3′ 
M13 Forward primer 5′- GTAAAACGACGGCCAG -3′ 
M13 Reverse primer 5′- CAGGAAACAGCTATGAC -3′ 
Tol2 Forward primer (Tol2_F) 5′- TCAAGTGAAAGTACAAGTACTTAGG -3′ 
Tol2 Reverse primer (Tol2_R_b) 5′- CGTGCAGTTCATTATTAGTT -3′ 
EGFP Forward primer (EGFP_F) 5′- ATGGTGAGCAAGGGCGAGGA -3′ 
EGFP Reverse primer (EGFP_R) 5′- CGTCCTTGAAGAAGATGGTGCG -3′ 
Expression Clone Forward primer 
(Expr_F) 5′- CAGTTGTTGGCACACCCAGC -3′ 
Expression Clone Reverse primer 
(Expr_R) 5′- TTTACGTCGCCGTCCAGCTC -3′ 
DsRed Forward primer (DsRed_F) 5′- TCTAGGTTCATCGCATGCAG -3′ 
DsRed Reverse primer (DsRed_R) 5′- GCCGTCCTCGAAGTTCATC -3′ 
Z60737 Forward primer 5′- AGGGCATTAGGATCTCCGTT -3′ 
Z60737 Reverse primer 5′- TGTGACTGACAGTCAAACCTGA -3′ 
Middle Entry Reverse primer (ME_Rev) 5′- AAAGTGAGGCTGAGACGC -3′ 
3′ Entry Reverse primer (3E_Rev) 5′- TATTTGTGAGCCAGGGCATT -3′ 
hTNFα Enhancer Forward primer 5′- CCCGCGATGGAGAAGAAACC -3′ 
hTNFα Enhancer Reverse primer 5′- TGTGCCAACAACTGCCTTTA -3′ 
zTNFαTomato Forward primer 
(zTNFaTom_F) 5′- TTTCAGTGCAATCCGCTCAATCTG -3′ 
zTNFαTomato Reverse primer 







THERMOCYCLER PROTOCOLS FOR PCR AMPLIFICATION 
 







Initial denaturation at 94°C (3′); 40 cycles of denaturing, annealing, 
and elongation: 94°C (15′′); 55°C (30′′); 72°C (30′′); an additional 
elongation at 72°C (10′);  and cool down of 10°C (60′) 
modified CA55S 
Initial denaturation at 94°C (3′); 40 cycles of denaturing, annealing, 
and elongation: 94°C (15′′); 55°C (30′′); 72°C (75′′); an additional 
elongation at 72°C (10′);  and cool down of 10°C (60′) 
EGFP 
Initial denaturation at 95°C (2′); 30 cycles of denaturing, annealing, 
and elongation: 95°C (30′′); 55°C (30′′); 72°C (60′′); an additional 
elongation at 72°C (2′); and cool down of 10°C (60′) 
EXPR 
Initial denaturation at 95°C (2′); 35 cycles of denaturing, annealing, 
and elongation: 95°C (20′′); 60°C (20′′); 72°C (30′′); an additional 
elongation at 72°C (5′); and cool down of 10°C (60′) 
DSRED 
Initial denaturation at 95°C (2′); 35 cycles of denaturing, annealing, 
and elongation: 95°C (20′′); 55°C (20′′); 72°C (30′′); an additional 
elongation at 72°C (5′); and cool down of 10°C (60′) 
ZTNF 
Initial denaturation at 95°C (3′); 35 cycles of denaturing, annealing, 
and elongation: 95°C (15′′); 60°C (30′′); 72°C (60′′); an additional 
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